Company Description
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.
The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019.
MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 27, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 133 |
| CEO | Christopher Kroeger |
Contact Details
Address: 800 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 617 984 6300 |
| Website | maplightrx.com |
Stock Details
| Ticker Symbol | MPLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1770069 |
| CUSIP Number | 56565P103 |
| ISIN Number | US56565P1030 |
| Employer ID | 83-2163243 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. | Founder, President, Chief Executive Officer and Director |
| Dr. Robert C. Malenka M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Erin Pennock Foff M.D., Ph.D. | Chief Medical Officer |
| Dr. Karoly Nikolich Ph.D. | Founder and Member of Advisory Board |
| Dr. Karl Deisseroth M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. James Woodruff Lillie Ph.D. | Chief Scientific Officer |
| Kristopher L. Hanson J.D. | General Counsel and Secretary |
| Dr. Anatol Kreitzer Ph.D. | Chief Discovery Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | EFFECT | Notice of Effectiveness |
| Sep 23, 2026 | 424B3 | Prospectus |
| Sep 18, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 16, 2026 | 144 | Filing |
| Sep 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 20, 2026 | SCHEDULE 13G | Filing |
| Aug 18, 2026 | SCHEDULE 13D/A | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 3, 2026 | SCHEDULE 13D/A | Filing |